Abstract
Purpose: In the USA, personal protective equipment (PPE) that claims to resist viral penetration, must pass the American Society for Testing and Materials (ASTM) F1671 test method which uses a standard plaque assay (SPA) to quantify Phi-X174 virus. SPA is labor-intensive, time-consuming, limiting its practicality for rapid screening. This study evaluates whether a viable quantitative Real-time Poly-merase Chain Reaction (v-qPCR), targeting two amplicon size (332bp, and 1644bp) can serve as a rapid screening tool for PPE during shortages. Design/methodology/approach: Phi-X174 was subjected to heat and UVC treatments known to damage viral capsids and/or genomes. Samples were treated with propidium monoazide (PMA), and viral quantities were assessed using v-qPCR and SPA. Quantification outcomes from v-qPCR were compared against SPA titers. Findings: v-qPCR targeting the 332 bp fragment produced quantification results consistent with SPA, with the greatest difference being about one order of magnitude (3.99×10ˆ10± 4.09×10ˆ9 Particle-Forming Unit/ml (PFU/ml) vs. 2.98×10ˆ9 ± 1.80×10ˆ9 PFU/mL). The v-qPCR method demonstrated a limit of detection of 500 viral copies for the 332 bp target. The 1644 bp amplicon showed higher variability and lower sensitivity. Originality/value: This study is the first to assess v-qPCR's potential for PPE testing by evaluating amplicon size effects and comparing quantification to SPA under standardized damaging conditions. The results suggest that v-qPCR offers a practical screening alternative to support rapid PPE evaluation.

This publication has 23 references indexed in Scilit: